Hydrazine Sulfate reduces cachexia
A substance that has been studied as a treatment for cancer and as a treatment for cachexia (body wasting) associated with advanced cancer.
National Cancer Institute
This study states: There is good evidence that hydrazine sulfate inhibits gluconeogenesis. Therefore, it may play a role in reducing the severity of cachexia and in improving the quality of life of cancer patients.
This study says: On the basis of observations available, Sehydrin may be assessed as an alternative drug for the treatment and symptomatic therapy of patients with some advanced solid tumours and malignant lymphomas at a disease stage when the other methods of treatment can not be used.
This study found: In a series of 84 various evaluable disseminated cancer patients treated with hydrazine sulfate as a result of a pharmaceutical-sponsored investigational new drug (IND) study, it was found that 59/84 or 70 % of the cases improved subjectively and 14/84 or 17 % improved objectively.
Subjective responses included increased appetite with either weight gain or cessation of weight loss, increase in strength and improved performance status and decrease in pain. Objective responses included measurable tumor regression, disappearance of or decrease in neoplastic-associated disorders and long-term (over 1 year) ‘stabilized condition’. Of the overall 59 subjective improvements 25 (42 %) had no concurrent or prior (within 3 months) anticancer therapy of any type. Of the 14 objective improvements 7 (50 %) had no concurrent or prior anticancer therapy. Of the remaining cases in which there was either concurrent or prior anticancer therapy, improvements occurred only after the addition of hydrazine sulfate to the treatment regimen. Duration of improvement was variable, from temporary to long-term and continuing.
This study says: The results of Sehydrin administration in 46 patients with malignant and 6 patients with benign tumors of the brain are presented. Pronounced therapeutic effect for the whole group was 63.5% and 73%, if partial regression of neurological symptoms in the entire brain and separate foci is considered. The percentages for patients with malignant tumors only were 61 and 71.1, respectively. Since Sehydrin has virtually no significant untoward side-effects, it is considered a most safe medication for the management of brain tumors. It is recommended in cases of inoperable tumor and for post-operative adjuvant chemotherapy with a view toward extending the patient’s survival time and improving the quality of life…
In 38 patients with glioblastomas Sehydrin administration resulted in at least tumor stabilization and tumor regression in 27 (71%). Regression of symptoms and improvement in the general well-being were observed as follows: a decrease in headaches and dyspepsia, and a partial restoration of cranial nerve function as well as sensory and motor function. Survival time was increased from 9 to 16 months (average, 13+0.6 months)–twice the survival as after usual surgery. Eight (30%) of those 27 patients survived more than 19 months and one patient–more than 30 months. Sehydrin therapy was ineffective in only 11 of 38 patients with malignant glioblastomas; these patients died from tumor progression in 4 to 5 months after surgery.
Conclusion: This experience with hydrazine sulfate in an advanced cancer population points to a potential role for this agent in maintaining weight in patients with cancer cachexia.
EFFICACY OF HYDRAZINE SULFATE IN THE TREATMENT OF CANCER
Source: Syracuse Cancer Research Institute, Syracuse, N.Y.
This is the first official notice of the efficacy of hydrazine sulfate in the treatment of human cancer.
For years the Syracuse Cancer Research Institute has known of and publicized the efficacy and safety of hydrazine sulfate in the treatment of human cancer.
Controlled clinical trials of this drug performed from 1976 through 1990 in accordance with internationally accepted standards (the Helsinki Declaration) demonstrated that for every million late-stage, unresponsive cancer patients treated with hydrazine sulfate, the drug developed by the SCRI, a half-million (50%) will respond with measurable symptomatic improvement, 400,000 (40%) will obtain tumor stabilization or regression (either no further tumor growth or tumor shrinkage), and some will go on to long term (>10 years) “complete response,” i.e., survival. These controlled clinical studies included ten years of Phase III randomized, placebo-controlled trials at Harbor-UCLA Cancer Center in Torrance, CA and 17 years of multicentric Phase II equivalent trials headquartered at the N. N. Petrov Research Institute of Oncology in St. Petersburg, Russia. These positive trials were all published in premier American peer-reviewed medical journals.
Only three controlled trials, all sponsored by the National Cancer Institute, have failed to show positive effects. However, all three trials were in violation of Principle 1 (the “generally accepted standards” rule) of the Helsinki Declaration by virtue of their use of incompatible agents (medications) with the test drug and therefore declared by this Declaration to have no scientific standing. Despite this, the NCI has consistently published the negative outcome of its sponsored trials, with the result that the use of this drug has become controversial.
No further controlled studies could be done. For this reason the SCRI felt it necessary to await further news of confirmation of drug effect before being justified in making a formal announcement to the public of drug efficacy.
Over the past 20 years the SCRI has acted as a central headquarters in receiving reports from thousands of doctors, veterinarians and individuals regarding their patients, loved ones and pets with cancer, treated with hydrazine sulfate alone.
At this time we can disclose to the public that the results of all these single case reports seem to be identical to the combined controlled clinical studies of Harbor-UCLA and the N. N. Petrov Research Institute of Oncology quoted above: 50% measurable symptomatic improvement, 40% tumor stabilization or regression, 5%-10% long term “complete response,” i.e., survival. And these are in very advanced patients. Even better results have been reported in early or newly diagnosed patients.
Have any side effects or risks been reported from hydrazine sulfate?
In general, the reported side effects of hydrazine sulfate treatment have been mild to moderate. Most side effects are reported to end when treatment with hydrazine sulfate is stopped. Some animal studies, however, suggest that hydrazine sulfate may be highly toxic (harmful) when combined with either alcohol or barbiturates (drugs with sedative and hypnotic effects).
Most of the side effects caused by hydrazine sulfate have involved the nervous system and gastrointestinal tract. These side effects include the following:
- Nausea and/or vomiting.
- Abnormal feelings in the arms and legs (such as burning or prickling).
- Nerve inflammation.
- Impaired fine motor function (such as trouble writing).
- Dry skin and/or itching.
- Being unable to sleep.
- Abnormally low blood sugar.
One case of fatal liver and kidney failure and one case of severe injury to the brain have been linked to the use of hydrazine sulfate.
Source: National Cancer Institute
Where can I get this treatment and more information?
Hydrazine Sulphate and Cesium Chloride are sold as dietary supplements in health food stores and online.